Scienture CEO says focused on execution, growth, expansion for years ahead

SCIENTURE (SCNX) HOLDINGS provided an annual update from CEO, Surendra Ajjarapu, to its stockholders, which read in part, “This time last year, Scienture Holdings was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through our wholly-owned subsidiary, Integra Pharma Solutions, which is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. We completed a sale of assets of our subsidiary TRXaDE to Micro Merchant Systems for $22.5M in 1Q24 and entered into a business combination with Scienture, a private branded and specialty pharmaceutical company, in an all-stock transaction valued at $103M. This completed our transformation to a company focused on the development of a novel and innovative specialty product pipeline that provides comprehensive access and disease management solutions to patients, caregivers and the healthcare system. Today, we are a fully fitted branded and specialty pharmaceutical company through our wholly-owned Scienture subsidiary, with two FDA approved commercial products to be launched in the second half of 2025. We received NDA approval for our first in-house product from the FDA and completed the strategic acquisition of a previously approved product in March 2025. We have put together an accomplished commercial operations infrastructure and go to market capabilities, for bringing novel and innovative brand products to the market. Our R&D focus continues to be in place with our proprietary product pipeline in development by leveraging the 505b-2 NDA and BLA regulatory pathways, identifying and contracting with key technology partners and service providers for product development, manufacturing and clinical operations. We are also in the process of divesting our legacy subsidiaries related to healthcare IT and pharmaceutical wholesaler operations, to fully focus on the branded and specialty pharma segment…Over the next 12 months, we will be focused on: Successful launches of Scienture two commercial products to obtain meaningful market share and providing a platform for growth and profitability. IQVIA data indicates a combined total annual sales of $481M for Losartan and Naloxone in the US market. Continue to execute seamlessly on all our product development initiatives and drive relentlessly through to regulatory filings and approval Continue to leverage our deep industry networks to identify and close on potential revenue and margin opportunities through business development and licensing. Continue to empower and strategically enhance our workforce to deliver strong results.”